NEW YORK — Mologic said on Monday that it has signed an agreement for the manufacture of its ELISA-based SARS-CoV-2 test with Omega Diagnostics.
Under the material transfer agreement between the UK-based companies, Omega will immediately begin manufacturing the lab-based test. Mologic said it will offer the test in the UK, as well as in Africa through an alliance with the Institut Pasteur de Dakar in Senegal, with access prioritized for health services and key worker communities.
Mologic said that its test — which was validated in collaboration with the Liverpool School of Tropical Medicine and St George's, University of London — is expected to provide up to 46,000 results per day.
Mologic is also developing point-of-care assays for SARS-CoV-2 that use blood and saliva specimens.